Miro1 protein identified as potential target for type 2 diabetes research

Researchers have identified the Miro1 protein as a potential target for future type 2 diabetes treatments. A study published in Nature Communications indicates that Miro1 accumulates in the skeletal muscle of individuals with type 2 diabetes and may contribute to insulin resistance.

In preclinical models, removing the Miro1 protein—which is located on the outer membrane of mitochondria—restored insulin responsiveness in muscle tissue. Additionally, a randomized trial involving people with obesity and type 2 diabetes found that aerobic exercise resulted in lower muscle Miro1 levels, alongside improved insulin sensitivity and muscle energy production.

The research was led by Dr. John P. Kirwan, currently the executive director of the Harold Hamm Diabetes Center at the University of Oklahoma, during his time at the Pennington Biomedical Research Center. While these findings offer a new direction for molecular research, experts note that further studies are required to determine if targeting Miro1 can be safely translated into human medical treatments.